FindTrial
Sign In

Administration of intrauterine Misoprostol in decreasing the blood loss in cesarean section

Effect of Prophylactic Addition of Intrauterine Misoprostol to the Standard oxytocin versus standard oxytocin alone For Prevention of primary PPH during Caesarean Section : A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/03/050948
Enrollment
300
Registered
2023-03-21
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O679- Intrapartum hemorrhage, unspecified

Interventions

Intervention1: Intrauterine Tab.Misoprostol: Intrauterine route , 400 mcg in Intervention Group Intervention2: Tab.Misoprostol 400 mcg: intrauterine route Tab.Misoprostol 400 mcg Control Intervention1

Sponsors

Aiims Jodhpur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.18-35 yesar age 2.singleton pregnancy 3.37-40 week POG 4.no h/o coagulopathy 5.no h/o hypersensitivity to prostaglandins 6.consento participate in study

Exclusion criteria

Exclusion criteria: 1.Preterm or post term Pregnancy 2.Grandmultipara( >5 Pregnancy) 3.H/o Coagulopathy 4.H/o hypersensitivity to Prostaglandins 5.Risk of Obstetric Hemmorhhage 6.H/O Anemia

Design outcomes

Primary

MeasureTime frame
1.To estimate of the amount of blood loss during and within 24 hour of caesarean delivery following administration of intrauterine misoprostol plus intravenous oxytocin compared to intravenous oxytocin alone.Timepoint: from the delivery of the delivery of the baby till the 24 hours after the cesarean section—

Secondary

MeasureTime frame
Incidence of PPH Side effects of Tab.Misoprostol Need of Blood TransfusionTimepoint: 18 month—

Countries

India

Contacts

Public ContactAiims Jodhpur

AIIMS Jodhpur

meenakshigothwal@gmail.com9212126860

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026